Albumin for Adult <scp>ICU</scp> Patients With Shock: Protocol for the <scp>INCEPT</scp> ‐Albumin Platform Trial Domain
INCEPT-Albumin will with high probability provide conclusive results and inform clinical practice regarding albumin versus no albumin use in adult acutely admitted ICU patients with shock.
Authors
- Rikke Faebo Larsen
- Carmen Andrea Pfortmueller (ORCID: https://orcid.org/0000-0003-0326-2770)
- Maj‐Brit Nørregaard Kjær (ORCID: https://orcid.org/0000-0002-6536-0504)
- Praleene Sivapalan (ORCID: https://orcid.org/0000-0002-0442-0032)
- Aksel Karl Georg Jensen (ORCID: https://orcid.org/0000-0002-1459-0465)
- Theis Lange
- Lasse Grønningsæter
- Anders Perner
- Maria Cronhjort
- Frederik Keus
- Martin Ingi Sigurdsson
- Morten Hylander Møller
- Karen Louise Ellekjær
- Benjamin Skov Kaas‐Hansen
Institutions
- University of Copenhagen (DK)
- Oslo University Hospital (NO)
- University Medical Center Groningen (NL)
- University of Helsinki (FI)
- University of Iceland (IS)
- Helsinki University Hospital (FI)
- University Hospital of Bern (CH)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Karolinska Institutet (SE)
- Stockholm South General Hospital (SE)
- National University Hospital of Iceland (IS)
- Centre for Research in Intensive Care (DK)
Publication Details
- Journal
- Acta Anaesthesiologica Scandinavica
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1111/aas.70203
- Primary Topic
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- Edwards Lifesciences
- Dagmar Marshalls Fond
- CSL Behring
- Les Laboratories Pierre Fabre
- Novo Nordisk
- Astellas Pharma
- Rigshospitalet
- Novo Nordisk Fonden